Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Castle Biosciences Inc is a diagnostics & research business based in the US. Castle Biosciences shares (CSTL) are listed on the NASDAQ and all prices are listed in US Dollars. Castle Biosciences employs 311 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $35.56 |
|---|---|
| 52-week range | $31.51 - $107.69 |
| 50-day moving average | $42.53 |
| 200-day moving average | $60.92 |
| Wall St. target price | $81.29 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.24 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $35.56 from 2022-01-27
| 1 week (2022-01-21) | 5.83% |
|---|---|
| 1 month (2021-12-28) | -13.69% |
| 3 months (2021-10-28) | -44.34% |
| 6 months (2021-07-28) | -48.20% |
| 1 year (2021-01-28) | -48.10% |
|---|---|
| 2 years (2020-01-28) | 18.61% |
| 3 years (2019-01-24) | N/A |
| 5 years (2017-01-24) | N/A |
Valuing Castle Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Castle Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Castle Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.9 million.
The EBITDA is a measure of a Castle Biosciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $86.3 million |
|---|---|
| Gross profit TTM | $53 million |
| Return on assets TTM | -5.79% |
| Return on equity TTM | -10.29% |
| Profit margin | -34.46% |
| Book value | $16.28 |
| Market capitalisation | $896.6 million |
TTM: trailing 12 months
We're not expecting Castle Biosciences to pay a dividend over the next 12 months.
Over the last 12 months, Castle Biosciences's shares have ranged in value from as little as $31.51 up to $107.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Castle Biosciences's is 0.5837. This would suggest that Castle Biosciences's shares are less volatile than average (for this exchange).
Castle Biosciences, Inc. , a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas. .
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.